The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2024-09-14 DOI:10.1007/s12325-024-02972-0

Antoine Boustany, Paul Feuerstadt, Glenn Tillotson

{"title":"The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile","authors":"Antoine Boustany, Paul Feuerstadt, Glenn Tillotson","doi":"10.1007/s12325-024-02972-0","DOIUrl":null,"url":null,"abstract":"<div><p>This paper explores the intricate relationship between depression, gut dysbiosis, and <i>Clostridioides difficile</i> infections, collectively termed “The 3 Ds”. Depression is a widespread mental disorder increasing in prevalence. It is recognized for its societal burden and complex pathophysiology, encompassing genetic, environmental, and microbiome-related factors. The consequent increased use of antidepressants has led to growing concerns about their effects on the gut microbiome. Various classes of antidepressants and antipsychotics show antimicrobial activity, potentially leading to shifts in the gut microbiome and contributing to the development of dysbiosis. Dysbiosis, in turn, can predispose individuals to opportunistic infections like <i>C. difficile</i>, a significant healthcare concern due to its high recurrence rates and severe impact on patients' quality of life. Further, the link between antidepressant use and an increased risk of <i>C. difficile</i> infection (CDI) is explored and, finally, the emergence of live biotherapeutic products as novel treatment options for recurrent CDI is discussed.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 11","pages":"3982 - 3995"},"PeriodicalIF":3.4000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-02972-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02972-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

This paper explores the intricate relationship between depression, gut dysbiosis, and Clostridioides difficile infections, collectively termed “The 3 Ds”. Depression is a widespread mental disorder increasing in prevalence. It is recognized for its societal burden and complex pathophysiology, encompassing genetic, environmental, and microbiome-related factors. The consequent increased use of antidepressants has led to growing concerns about their effects on the gut microbiome. Various classes of antidepressants and antipsychotics show antimicrobial activity, potentially leading to shifts in the gut microbiome and contributing to the development of dysbiosis. Dysbiosis, in turn, can predispose individuals to opportunistic infections like C. difficile, a significant healthcare concern due to its high recurrence rates and severe impact on patients' quality of life. Further, the link between antidepressant use and an increased risk of C. difficile infection (CDI) is explored and, finally, the emergence of live biotherapeutic products as novel treatment options for recurrent CDI is discussed.

Abstract Image

查看原文本刊更多论文

3 Ds：抑郁症、菌群失调和艰难梭状芽孢杆菌

本文探讨了抑郁症、肠道菌群失调和艰难梭菌感染（统称为 "3D"）之间错综复杂的关系。抑郁症是一种广泛存在的精神疾病，发病率不断上升。它因其社会负担和复杂的病理生理学（包括遗传、环境和微生物相关因素）而被公认。随着抗抑郁药物使用的增加，人们越来越关注这些药物对肠道微生物组的影响。各种类型的抗抑郁药和抗精神病药具有抗菌活性，可能会导致肠道微生物群发生变化，并导致菌群失调。反过来，菌群失调又会使患者易患艰难梭菌等机会性感染，而艰难梭菌的高复发率和对患者生活质量的严重影响是医疗保健领域的一个重大问题。此外，还探讨了使用抗抑郁药与艰难梭菌感染（CDI）风险增加之间的联系，最后讨论了活生物治疗产品作为复发性艰难梭菌感染的新型治疗方案的出现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.